Searching for smart, safe news you can TRUST?

Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Searching for smart, safe news you can TRUST?

Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: George Frey/Getty Images

Congress recently put the pharmaceutical industry on the hook for more of seniors' drug costs, but the industry is pushing lawmakers to reverse that policy as part of a bill to address the opioid crisis.

The big picture: Congress voted earlier this year to shift billions of dollars in Medicare drug costs away from seniors and onto drug companies. Now, "PhRMA is begging" lawmakers to reverse that decision in unrelated opioids legislation, a GOP congressional aide said.

The details: A February spending bill required drugmakers to cover more of the costs seniors incur when they fall into Medicare's "donut hole."

  • It was a rare lobbying loss for the industry. Its leading trade group, the Pharmaceutical Research and Manufacturers of America, has been lobbying aggressively on the issue ever since.
  • After failing to get lawmakers to reverse the hit in subsequent spending bills, the industry's focus has now shifted to the opioids package being finalized by House and Senate leaders, according to lobbyists and congressional aides familiar with the process.
  • "Sounds like the size of the fix for pharma could be maybe 2-3x bigger than the opioids funding," a House Democratic aide said.

Industry is trying to broker a compromise, those sources said: Eliminate the multibillion-dollar tab drug companies would absorb for Medicare's "donut hole," and in exchange industry would accept a version of a bill designed to stop brand-name drugmakers from blocking generic competitors.

Yes, but: None of this has anything to do with the opioid crisis, which has so far been a rare example of bipartisan agreement. And there's reason to be highly skeptical Democrats would go along with the industry's latest request.

  • "If you're a Democrat, why do you want to do this?" one pharmaceutical lobbyist asked.
  • It's also unclear whether Republicans will go along. The GOP congressional aide said his party won't force the issue unless PhRMA can lock in Democratic support on its own.

Go deeper

Dan Primack, author of Pro Rata
2 hours ago - Health

Moderna exec says children could be vaccinated by mid-2021

Tal Zaks, chief medical officer of Moderna, tells "Axios on HBO" that a COVID-19 vaccine could be available for children by the middle of next year.

Be smart: There will be a coronavirus vaccine for adults long before there is one for kids.

Updated 2 hours ago - Politics & Policy

Sen. Kelly Loeffler to return to campaign trail after 2nd negative test

Sen. Kelly Loeffler addresses supporters during a rally on Thursday. Photo: Jessica McGowan/Getty Images

Sen. Kelly Loeffler's (R-Ga.) campaign announced Monday that she "looks forward to getting back out on the campaign trail" after testing negative for COVID-19 for a second time, following earlier conflicting results.

Why it matters: Loeffler has been campaigning at events ahead of a Jan. 5 runoff in elections that'll decide which party holds the Senate majority. Vice President Mike Pence was with her on Friday.

Updated 7 hours ago - Politics & Policy

Key government agency says Biden transition can formally begin

General Services Administrator Emily Murphy. Photo: Alex Edelman/CNP/Getty Images

General Services Administrator Emily Murphy said in a letter to President-elect Joe Biden on Monday that she has determined the transition from the Trump administration can formally begin.

Why it matters: Murphy, a Trump appointee, had come under fire for delaying the so-called "ascertainment" and withholding the funds and information needed for the transition to begin while Trump's legal challenges played out.